N-Acetylcysteine for Patients With COPD and ChronicBronchitis
Status:
Unknown status
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
N-acetylcysteine (NAC) is described as having mucolytic and antioxidant properties. It is
widely prescribed for patients with chronic obstructive pulmonary disease (COPD),
particularly for those who have accompanying symptoms of chronic cough and sputum production.
Randomized, placebo controlled indicate that it is safe and that it may have some clinical
benefit when used at relatively low doses. It is postulated that substantially higher doses
of NAC will be well-tolerated and will provide better symptom control while also decreasing
blood makers of oxidant stress and inflammation.
Phase:
N/A
Details
Lead Sponsor:
Center for Veterans Research and Education Minnesota Veterans Medical Research and Education Foundation